These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 30377997)
61. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Kioka H; Yamada T; Mine T; Morita T; Tsukamoto Y; Tamaki S; Masuda M; Okuda K; Hori M; Fukunami M Heart; 2007 Oct; 93(10):1213-8. PubMed ID: 17344327 [TBL] [Abstract][Full Text] [Related]
62. Regional myocardial sympathetic dysinnervation in arrhythmogenic right ventricular cardiomyopathy. An analysis using 123I-meta-iodobenzylguanidine scintigraphy. Wichter T; Hindricks G; Lerch H; Bartenstein P; Borggrefe M; Schober O; Breithardt G Circulation; 1994 Feb; 89(2):667-83. PubMed ID: 8313555 [TBL] [Abstract][Full Text] [Related]
63. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy]. Yoshita M; Hayashi M; Hirai S Rinsho Shinkeigaku; 1997 Jun; 37(6):476-82. PubMed ID: 9366173 [TBL] [Abstract][Full Text] [Related]
64. Cardiac 123I-MIBG scintigraphy in heart failure. Agostini D; Verberne HJ; Hamon M; Jacobson AF; Manrique A Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):369-77. PubMed ID: 19088691 [TBL] [Abstract][Full Text] [Related]
65. The potential role of iodine-123 metaiodobenzylguanidine imaging for identifying sustained ventricular tachycardia in patients with cardiomyopathy. Klein T; Dilsizian V; Cao Q; Chen W; Dickfeld TM Curr Cardiol Rep; 2013 May; 15(5):359. PubMed ID: 23536110 [TBL] [Abstract][Full Text] [Related]
66. Creation of mortality risk charts using 123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models. Nakajima K; Nakata T; Matsuo S; Jacobson AF Eur Heart J Cardiovasc Imaging; 2016 Oct; 17(10):1138-45. PubMed ID: 26705487 [TBL] [Abstract][Full Text] [Related]
73. [Cardiac sympathetic dysfunction in Parkinson's disease--relationship between results of 123I-MIBG scintigraphy and autonomic nervous function evaluated by the Valsalva maneuver]. Oka H; Yoshioka M; Morita M; Mochio S; Inoue K Rinsho Shinkeigaku; 2003 Aug; 43(8):465-9. PubMed ID: 14658397 [TBL] [Abstract][Full Text] [Related]
74. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. Arora R; Ferrick KJ; Nakata T; Kaplan RC; Rozengarten M; Latif F; Ng K; Marcano V; Heller S; Fisher JD; Travin MI J Nucl Cardiol; 2003; 10(2):121-31. PubMed ID: 12673176 [TBL] [Abstract][Full Text] [Related]
75. Cardiac I123-MIBG correlates better than ejection fraction with symptoms severity in systolic heart failure. Miranda SM; Moscavitch SD; Carestiato LR; Felix RM; Rodrigues RC; Messias LR; Azevedo JC; Nóbrega AC; Mesquita ET; Mesquita CT Arq Bras Cardiol; 2013 Jul; 101(1):4-8. PubMed ID: 23917506 [TBL] [Abstract][Full Text] [Related]
76. Risk stratification in heart failure using ¹²³I-MIBG. Currie GM; Iqbal B; Wheat JM; Wang L; Trifunovic M; Jelinek HF; Kiat H J Nucl Med Technol; 2011 Dec; 39(4):295-301. PubMed ID: 21969356 [TBL] [Abstract][Full Text] [Related]
77. Clinical evaluation of no-carrier-added meta-[123I]iodobenzylguanidine for myocardial scintigraphy. Knickmeier M; Matheja P; Wichter T; Schäfers KP; Kies P; Breithardt G; Schober O; Schäfers M Eur J Nucl Med; 2000 Mar; 27(3):302-7. PubMed ID: 10774882 [TBL] [Abstract][Full Text] [Related]